Aerie Pharmaceuticals Inc (OQ:AERI)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 4301 Emperor Blvd Ste 400
DURHAM NC 27703-7615
Tel: N/A
IR: See website
Key People
Vicente Anido
Chairman of the Board, Chief Executive Officer
Thomas A. Mitro
President, Chief Operating Officer
Casey C. Kopczynski
Co-Founder, Chief Scientific Officer
Richard J. Rubino
Chief Financial Officer, Treasurer, Secretary
John W. LaRocca
General Counsel and Assistant Secretary
Nina Ohara
Director of Marketing
David A. Hollander
Chief Research and Development Officer
Business Overview
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.
Financial Overview
For the three months ended 31 March 2020, Aerie Pharmaceuticals Inc revenues increased 87% to $20.3M. Net loss increased 2% to $49.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Interest expense increase from $798K to $6.4M (expense), General and administrative -Other increase of 10% to $30M (expense).
Employees: 380 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $552.24M as of Mar 31, 2020
Annual revenue (TTM): $79.38M as of Mar 31, 2020
EBITDA (TTM): -$177.12M as of Mar 31, 2020
Net annual income (TTM): -$200.76M as of Mar 31, 2020
Free cash flow (TTM): -$149.87M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 46,468,255 as of May 1, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization